Nomura Funds Ireland –
Global High Conviction Fund
Truly active equity exposure
Nomura Funds Ireland – Global High Conviction Fund
Morningstar Overall Ratings as at 30-09-2021. Copyright © 2021 Morningstar UK Limited. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. Morningstar rating based on the lead share class: Nomura Funds Ireland – Global High Conviction I USD.
Overview
Equity investors have long felt short-changed by fund managers as so few have proved able to outperform indices on a consistent basis. This has driven many to move to a ‘passive’ approach, turning to index trackers and ETFs.
Conversely, we believe that this secular shift is leading to growing opportunities for focused stock-pickers. However, to take advantage of these opportunities, investors need to focus on both the quality of the underlying assets and their intrinsic value.
Our Global High Conviction team is able to drill down on potential opportunities in markets across the world.
Investment Approach
- Bottom-up focusing on quality stocks trading at discount valuations
- Only around 20 stock positions – active share above 90%
- No style bias and low turnover
- ESG embedded into the investment process
Reasons to Invest
- Truly active investing
- Unconstrained approach – the team are able to invest across global equity markets
- Large, established team emphasising rigorous stock research
Potential significant risks
Emerging markets or less developed countries may face more political, economic or structural challenges than developed countries.
| Investment Objective | To achieve long-term capital growth through investment in a highly concentrated, actively managed portfolio of global equities. Our approach is bottom-up as we seek to invest in quality companies trading at a discount to intrinsic value. We believe that successful portfolio diversification can be achieved with around 20 stocks. |
||||||
| Fund Size | USD 115.5 million (as at 30.09.2021) |
||||||
| Investment Company | Nomura Asset Management U.K. Ltd. |
||||||
| Fund Managers |
|
||||||
| Launch Date | 21.12.2015 |
||||||
| Base Currency | USD |
||||||
| Universe Sector | Morningstar: Global Large-Cap Blend Equity IA Sector: Global |
||||||
| Benchmark | MSCI All Countries World |
||||||
| Domicile | Ireland (Nomura Funds Ireland Plc) |
||||||
| Lead ISINs | Institutional ‘I’ USD – IE00BD4DXL75 Institutional ‘I’ GBP – IE00BD4DXN99 Retail ‘A’ USD – IE00BD4DXF16 Retail ‘A’ EUR – IE00BD4DXG23 For additional share class information, please contact us. |
|
Tom Wildgoose, Co-Manager Tom is the Head of Equity Investment at Nomura Asset Management U.K. Ltd and has been with the firm since 2007, having previously been a management consultant with Deloitte Consulting and then PA Consulting for 7 years. He became Head of Research in 2011 and then Head of Equities in 2014. Tom has been an equity investor for 17 years and has managed sector model portfolios internally as an analyst since joining NAM. He holds a Masters of Engineering (Durham University, First Class), a Masters in Computing (Imperial College, London), is a CFA Charterholder as well as being an exam qualified management accountant. |
|
Ilan Chaitowitz, Co-Manager Ilan has been with Nomura Asset Management U.K. Ltd since 2012 having previously been an Equity Analyst at JPMorgan Cazenove and subsequently a Partner at Redburn Partners. He has been an equity investor for 19 years and has been co-managing the NAM Healthcare Sector fund since early 2014. Ilan holds a Master of Arts in Natural Sciences (Cambridge University), a Masters in Clinical Drug Development (Barts & The London School of Medicine, Distinction) and is a CFA Charterholder. |
| Fund | Monthly Factsheet | Fund Snapshot | Commentary | ||
|---|---|---|---|---|---|
| I USD |
|
|
|
||
| I GBP |
|
|
For a full list of available share class documents including KIIDs, please visit our fund documents page.
The lead share class fund literature is shown first in the above list. If any literature is not available in the above list for the share class you are invested in/interested in, please contact NAMupdates@nomura-asset.eu
Nomura Funds Ireland plc is an open-ended investment company with variable capital, incorporated in Ireland on 13th April, 2006 under the Act with registration number 418598. The Fund has been authorised by the Central Bank as an UCITS pursuant to the UCITS Regulations. The Fund is structured as an umbrella fund consisting of different Sub-Funds each comprising one or more Classes. The Fund has segregated liability between each of its Sub-Funds.
Full information on the presented fund, which is relevant for an investment decision can be found in the fund´s most recent sales prospectus, the Key Investor Information Documents (KIIDs) and annual and semi-annual reports. The KIIDs are available in the official language of the countries in which the fund is registered for distribution. This fund displays higher volatility due to its composition / the techniques used by the fund management, i.e. unit prices can fluctuate upwards or downwards within short periods of time. Performance in the past is no guarantee of future success. There can be no guarantee that the fund´s investment objective will actually be achieved.
A summary of investor rights in English and information on collective redress mechanisms are available at https://www.nomura-asset.co.uk/download/funds/how-to-invest/Summary_of_investor_rights.pdf . Nomura Asset Management U.K. Limited may at any time decide to terminate arrangements it may have made for the marketing of units of a fund in a member state other than its home member state.
